Application of a live-cell reporter for CDK4/6 activity reveals rapid activity changes and reversibility in the cell-cycle entry signaling program.

Multi-omic profiling of tumor-infiltrating T cells provides new insights into the differences in the effectiveness of CDK4 inhibitor between human papillomavirus (HPV)-positive and HPV-negative head and neck squamous cell carcinoma patients.

An MTF2-containing subcomplex of Polycomb Repressive Complex 2 promotes cell cycle progression through repression of D-type cyclin expression in certain cellular contexts.

Dalpiciclib could partially abrogate ER nuclear transportation induced by pyrotinib in HER2+HR+ breast cancer and CALML5 could serve as a potential risk factor in the treatment of HER2+HR+ breast cancer.

Cells employ two strategies, adjusting both their cell cycle lengths and their growth rates in a size-dependent manner, to correct aberrations in cell size.

Bazedoxifene's SERD activities enable it to resist the impact of activating ESR1 mutations in breast cancer.

Arbidol is a ATR inhibitor to reduce the phosphorylation and activation of MCM2 at Ser108, and innhibits the cell proliferation of ESCC in vitro and in vivo through the DNA replication and cell cycle pathway.

Oversized mammalian cells reduce their growth efficiency by activating global protein degradation, which functions in parallel with the cell size checkpoints, to promote cell size homeostasis.